Key facts
- It has raised $4.2M; the latest was Seed Round in Aug 2024.
- Notable investors include US National Science Foundation, CONNECT(San Diego), Great Oaks Venture Capital, Johnson & Johnson Innovation - JLABS, Wisconsin Economic Development — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Lynx Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Lynx Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lynx Biosciences
Operator of a biotechnology company intended to offer personalized cancer treatments to patients. The company combines physiologically relevant suspension cell co-culture assays, automated microfluidics and deep learning analytics with the goal of rapidly advancing drug candidates, enabling blood cancer patients and multiple myeloma patients to receive a response on clinical treatment.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2013
- Employees
- 12
- Website
- lynx.bio/
- Ownership
- Privately Held (backing)
Lynx Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lynx Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lynx Biosciences in its N-PORT filings yet. We sweep new filings monthly.